---
input_text: 'A phase 1b study evaluating the safety and preliminary efficacy of berzosertib
  in combination with gemcitabine in patients with advanced non-small cell lung cancer.
  OBJECTIVES: Berzosertib (formerly M6620, VX-970) is an intravenous, highly potent
  and selective, first-in-class ataxia telangiectasia and Rad3-related (ATR) protein
  kinase inhibitor. We assessed the safety, tolerability, preliminary efficacy, and
  pharmacokinetics (PK) of berzosertib plus gemcitabine in an expansion cohort of
  patients with advanced non-small cell lung cancer (NSCLC). The association of efficacy
  with TP53 status and other tumor markers was also explored. MATERIALS AND METHODS:
  Adult patients with advanced histologically confirmed NSCLC received berzosertib
  210 mg/m2 (days 2 and 9) and gemcitabine 1000 mg/m2 (days 1 and 8) at the recommended
  phase 2 dose established in the dose escalation part of the study. RESULTS: Thirty-eight
  patients received at least one dose of study treatment. The most common treatment-emergent
  adverse events were fatigue (55.3%), anemia (52.6%), and nausea (39.5%). Gemcitabine
  had no apparent effect on the PK of berzosertib. The objective response rate (ORR)
  was 10.5% (4/38, 90% confidence interval [CI]: 3.7-22.5%). In the exploratory analysis,
  the ORR was 30.0% (3/10, 90% CI: 9.0-61.0%) in patients with high loss of heterozygosity
  (LOH) and 11.0% (1/9, 90% CI: 1.0-43.0%) in patients with low LOH. The ORR was 33.0%
  (2/6, 90% CI: 6.0-73.0%) in patients with high tumor mutational burden (TMB), 12.5%
  (2/16, 90% CI: 2.0-34.0%) in patients with intermediate TMB, and 0% (0/3, 90% CI:
  0.0-53.6%) in patients with low TMB. CONCLUSIONS: Berzosertib plus gemcitabine was
  well tolerated in patients with advanced, pre-treated NSCLC. Based on the observed
  clinical efficacy, future clinical trials should involve genomically selected patients.'
raw_completion_output: |-
  primary_disease: Non-small cell lung cancer

  medical_actions: evaluating safety and preliminary efficacy of berzosertib in combination with gemcitabine; assessed safety, tolerability, preliminary efficacy, and pharmacokinetics; received berzosertib 210 mg/m2 (days 2 and 9) and gemcitabine 1000 mg/m2 (days 1 and 8); exploring the association of efficacy with TP53 status and other tumor markers

  symptoms: fatigue; anemia; nausea

  chemicals: berzosertib; gemcitabine

  action_annotation_relationships: evaluating safety and preliminary efficacy of berzosertib in combination with gemcitabine TREATS Non-small cell lung cancer; received berzosertib 210 mg/m2 (days 2 and 9) TREATS Non-small cell lung cancer; received gemcitabine 1000 mg/m2 (days 1 and 8) TREATS Non-small cell lung cancer
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  received gemcitabine 1000 mg/m2 (days 1 and 8) TREATS Non-small cell lung cancer

  ===

extracted_object:
  primary_disease: MONDO:0005233
  medical_actions:
    - evaluating safety and preliminary efficacy of berzosertib in combination with
      gemcitabine
    - assessed safety, tolerability, preliminary efficacy, and pharmacokinetics
    - received berzosertib 210 mg/m2 (days 2 and 9) and gemcitabine 1000 mg/m2 (days
      1 and 8)
    - exploring the association of efficacy with TP53 status and other tumor markers
  symptoms:
    - HP:0012378
    - HP:0001903
    - HP:0002018
  chemicals:
    - berzosertib
    - CHEBI:175901
  action_annotation_relationships:
    - subject: evaluating safety and preliminary efficacy
      predicate: TREATS
      object: HP:0030358
      subject_qualifier: in combination with
      subject_extension: berzosertib, gemcitabine
    - subject: received berzosertib 210 mg/m2 (days 2 and 9)
      predicate: TREATS
      object: HP:0030358
      subject_extension: berzosertib
    - subject: received gemcitabine 1000 mg/m2 (days 1 and 8)
      predicate: TREATS
      object: HP:0030358
      subject_extension: CHEBI:175901
named_entities:
  - id: MONDO:0005086
    label: Renal cell carcinoma
  - id: MONDO:0003060
    label: Biliary tract cancer (BTC)
  - id: CHEBI:175901
    label: Gemcitabine
  - id: CHEBI:33364
    label: Platinum
  - id: MAXO:0000647
    label: chemotherapy
  - id: MONDO:0008840
    label: Ataxia Telangiectasia
  - id: MAXO:0010030
    label: Bone Marrow Transplantation
  - id: MAXO:0001001
    label: Gene Therapy
  - id: CHEBI:166830
    label: Acetyl-DL-leucine
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:4462
    label: Dexamethasone sodium phosphate
  - id: CHEBI:133021
    label: venetoclax
  - id: HP:0002721
    label: Immunodeficiency
  - id: HP:0002073
    label: progressive cerebellar ataxia
  - id: HP:0002013
    label: vomiting
  - id: HP:0002315
    label: headache
  - id: CHEBI:27899
    label: cisplatin
  - id: HP:0001903
    label: Anemia
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0001875
    label: Neutropenia
  - id: CHEBI:231342
    label: Ceralasertib
  - id: CHEBI:31355
    label: Carboplatin
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MONDO:0005184
    label: Pancreatic ductal adenocarcinoma (PDAC)
  - id: HP:0020174
    label: Drug resistance
  - id: MAXO:0000011
    label: Physical therapy
  - id: HP:0001251
    label: Ataxia
  - id: MONDO:0010150
    label: Head and neck squamous cell carcinomas (HNSCC)
  - id: MAXO:0000014
    label: Radiotherapy (RT)
  - id: HP:0010280
    label: Oral mucositis
  - id: HP:0002015
    label: Dysphagia
  - id: MONDO:0008876
    label: Bloom Syndrome (BS)
  - id: HP:0001510
    label: growth retardation
  - id: HP:0011793
    label: malignancies
  - id: MONDO:0004992
    label: Cancer
  - id: HP:0002664
    label: Cancer
  - id: CHEBI:27656
    label: Camptothecin (CPT)
  - id: CHEBI:63632
    label: Topotecan
  - id: CHEBI:4911
    label: Etoposide
  - id: CHEBI:231344
    label: Talazoparib
  - id: CHEBI:231616
    label: M4344
  - id: MONDO:0008433
    label: Small-cell lung cancer (SCLC)
  - id: HP:0030357
    label: Small-cell lung cancer (SCLC)
  - id: MONDO:0003778
    label: Inborn Errors of Immunity (IEI)
  - id: HP:0033141
    label: Severe SARS-CoV-2 infection
  - id: MAXO:0001017
    label: Vaccination
  - id: CHEBI:22907
    label: Bleomycin (BLM)
  - id: MONDO:0005494
    label: Triple-negative breast cancer (TNBC)
  - id: CHEBI:9555
    label: 6-thioguanine
  - id: CHEBI:4659
    label: Disulfiram
  - id: CHEBI:28694
    label: Cu
  - id: CHEBI:83766
    label: Olaparib
  - id: HP:0002894
    label: pancreatic cancer
  - id: MONDO:0005192
    label: Pancreatic Cancer
  - id: MONDO:0007254
    label: Breast Cancer
  - id: MAXO:0000127
    label: Genetic testing
  - id: HP:0003002
    label: Breast Cancer
  - id: MONDO:0008903
    label: lung cancer
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0005070
    label: Tumors
  - id: MAXO:0001394
    label: Oral administration
  - id: MONDO:0036501
    label: Refractory Cancer
  - id: CHEBI:45863
    label: Paclitaxel
  - id: MONDO:0018177
    label: Glioblastoma
  - id: MAXO:0000004
    label: Surgery
  - id: HP:0012174
    label: Glioblastoma
  - id: MONDO:0009807
    label: Osteosarcoma
  - id: MAXO:0001525
    label: Intravenous administration
  - id: CHEBI:132992
    label: radiosensitizers
  - id: MONDO:0005575
    label: colorectal cancer
  - id: CHEBI:62913
    label: poly (ADP-ribose) polymerase (PARP) inhibitors
  - id: HP:0010310
    label: Chylothorax
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:27563
    label: Arsenic
  - id: CHEBI:229924
    label: pifithrin-alpha (PFTalpha)
  - id: CHEBI:29678
    label: Sodium arsenite (NaAsO2)
  - id: CHEBI:41774
    label: Tamoxifen
  - id: MONDO:0004986
    label: Bladder cancer
  - id: HP:0009725
    label: Bladder cancer
  - id: MONDO:0968974
    label: Large B-Cell Lymphoma (LBCL)
  - id: MAXO:0000381
    label: Lymph node biopsy
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:8382
    label: Prednisone
  - id: MONDO:0005623
    label: AT (Autoimmune Thyroiditis)
  - id: MONDO:0008315
    label: Prostate Cancer
  - id: CHEBI:4672
    label: Docetaxel
  - id: HP:0012125
    label: Prostate Cancer
  - id: CHEBI:50914
    label: PI3K inhibitors
  - id: CHEBI:34936
    label: di-phenoxy acetamide (DPA) analogs
  - id: CHEBI:25555
    label: Compound DPA (7n)
  - id: HP:0000988
    label: rash
  - id: CHEBI:31348
    label: capecitabine
  - id: CHEBI:16044
    label: MET
  - id: HP:0100526
    label: Lung cancer
  - id: MONDO:0019600
    label: Xeroderma pigmentosum (XP)
  - id: CHEBI:131808
    label: Thymidine dimers
  - id: CHEBI:28300
    label: Glutamine
  - id: CHEBI:16856
    label: Glutathione
  - id: CHEBI:16810
    label: Alpha-ketoglutarate
  - id: HP:0000657
    label: Oculomotor apraxia
  - id: HP:0001266
    label: Choreoathetosis
  - id: CHEBI:4806
    label: Epigallocatechin-3-gallate (EGCG)
  - id: CHEBI:16240
    label: H2O2
  - id: CHEBI:229722
    label: RP-3500
  - id: CHEBI:135702
    label: Belotecan
  - id: CHEBI:229661
    label: Omaveloxolone
  - id: CHEBI:8863
    label: riluzole
  - id: MAXO:0000058
    label: pharmacotherapy
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0005140
    label: Epithelial ovarian cancer
  - id: HP:0002018
    label: Nausea
  - id: HP:0012378
    label: Fatigue
  - id: HP:0002039
    label: Anorexia
  - id: MONDO:0005233
    label: Non-small cell lung cancer
  - id: HP:0030358
    label: Non-small cell lung cancer
